Skip to contentB
BioCardia, Inc.
B
BCDABioCardia, Inc. Q2 2024 · 10-Q
Revenue$3.00K$3.00K−93.0% vs Q2 2023 Net Income-$1.65M-$1.65MN/M vs Q2 2023 EPS, diluted—
Operating Income-$1,649,000N/M Operating Cash Flowderived-$1,312,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioCardia, Inc. · CIK 925741 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,315,000N/M Margins · derivedOperating margin-54966.7%−46938.8 pt vs Q2 2023
Net margin-54866.7%−46903.9 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end